Copyright
©2010 Baishideng.
World J Gastroenterol. May 28, 2010; 16(20): 2484-2495
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2484
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2484
Case No. | Main medication | Dietary pattern | Days of remission | Reason for termination | On final attendance | |||||||||
Month 3 | Year 1 | Year 2 | On relapse | CDAI | CRP (mg/dL) | BMI (kg/m2) | Alb (g/dL) | Chol (mg/dL) | ChE (IU/mL) | Hemoglobin (g/dL) | ||||
1 | SSZ for 1 yr | SVD | SVD | SVD | 730 | Completion | 0 | 0.1 | 23.1 | 4.5 | 235 | 5684 | 14.4 | |
2 | Mesalamine | SVD | Omni | Omni | 301 | Relapse | 193 | 8.2 | 17.5 | 3.8 | 151 | 3262 | 13.8 | |
3 | Mesalamine | SVD | Omni | Omni | 367 | Relapse | 167 | 11.3 | 21.1 | 3.5 | 133 | 3551 | 10.0 | |
4 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 128 | 5.0 | 18.7 | 2.8 | 114 | 1113 | 9.3 | |
5 | SSZ for 1 yr | SVD | SVD | 523 | Moving | 39 | 0 | 19.4 | 4.5 | 194 | 5509 | 15.0 | ||
6 | Mesalamine | Omni | Omni | 191 | Relapse | 192 | 5.7 | 21.7 | 3.9 | 134 | 3052 | 7.9 | ||
7 | None | SVD | SVD | 442 | INFX for RA | 61 | 2.0 | 19.6 | 4.0 | 158 | 5068 | 10.9 | ||
8 | Mesalamine | SVD | SVD | SVD | 635 | Relapse | 174 | 7.6 | 19.1 | 3.1 | 88 | 2678 | 11.3 | |
9 | Mesalamine | Omni | Omni | Omni | 730 | Completion | 48 | 0.2 | 19.8 | 4.3 | 171 | 5461 | 15.2 | |
10 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 18 | 0.1 | 18.2 | 5.1 | 181 | 4659 | 16.3 | |
11 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 11 | 0 | 19.7 | 4.7 | 147 | 5215 | 13.9 | |
12 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 45 | 0 | 20.2 | 4.7 | 163 | 6268 | 11.3 | |
13 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 0 | 0 | 22.8 | 4.6 | 171 | 4770 | 15.6 | |
14 | Mesalamine | SVD | SVD | 666 | Ongoing | 27 | 0.1 | 19.3 | 4.7 | 188 | 6084 | 15.1 | ||
15 | Mesalamine | SVD | Omni | 560 | Ongoing | 0 | 0 | 22.6 | 4.8 | 185 | 5671 | 16.8 | ||
16 | Mesalamine | SVD | SVD | 440 | Ongoing | 19 | 1.9 | 21.8 | 4.4 | 141 | 5146 | 14.2 | ||
17 | Mesalamine | SVD | SVD | 397 | Ongoing | 32 | 2.0 | 22.5 | 3.6 | 216 | 2683 | 11.1 | ||
18 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 25 | 0.4 | 22.6 | 3.7 | 151 | 10222 | 11.1 | |
19 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 62 | 0 | 20.1 | 4.7 | 139 | 4391 | 13.3 | |
20 | None | SVD | SVD | SVD | 730 | Completion | 37 | 0.7 | 18.2 | 4.5 | 156 | 5655 | 13.2 | |
21 | SSZ | SVD | SVD | SVD | 730 | Completion | 16 | 0.1 | 19.0 | 4.9 | 205 | 6424 | 14.4 | |
22 | Mesalamine | SVD | Omni | Omni | 630 | Relapse | 118 | 5.1 | 22.1 | 3.5 | 84 | 3596 | 10.1 |
- Citation: Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J Gastroenterol 2010; 16(20): 2484-2495
- URL: https://www.wjgnet.com/1007-9327/full/v16/i20/2484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i20.2484